Efficacy of ATR inhibitors as single agents in Ewing sarcoma

Oncotarget

Volumn 7, Issue 37, 2016, Pages 58759-58767

  Nieto Soler, Maria ^a   Morgado Palacin, Isabel ^a   Lafarga, Vanesa ^a   Lecona, Emilio ^a   Murga, Matilde ^a   Callen, Elsa ^b   Azorin, Daniel ^c   Alonso, Javier ^d   Lopez Contreras, Andres J ^e   Nussenzweig, Andre ^b   Fernandez Capetillo, Oscar ^a,f  

^a Structural Biology and Biocomputing Programme   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

ATR; Cancer; DNA repair; Ewing sarcoma; Replication stress

Indexed keywords

ATR PROTEIN; AZ 20; CHECKPOINT KINASE 1; ETP 46464; HISTONE H2AX; MSC 253; OLAPARIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN, HUMAN; RNA BINDING PROTEIN EWS; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIZATION; EMBRYO; ERG GENE; EWING SARCOMA; EWING SARCOMA CELL LINE; EWS GENE; FLI1 GENE; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD50; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL LINE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE TUMOR; DNA DAMAGE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BONE NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; RNA, SMALL INTERFERING; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991325467     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11643     Document Type: Article

References (41)

1. Boveri T. Zur Frage der Entstehung Maligner Tumoren. Gustav Fischer, Jena. 1914:1-64
2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-921
3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-917
4. Halazonetis TD, Gorgoulis VG and Bartek J. An oncogeneinduced DNA damage model for cancer development. Science. 2008; 319(5868):1352-1355
5. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, D'Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B and Fernandez-Capetillo O. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011; 18(12):1331-1335
6. Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M, Fernandez-Capetillo O, Diehl JA and Brown EJ. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest. 2012; 122(1):241-252
7. Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee JE, Callen E, Gutierrez-Martinez P, Chen HT, Wong N, Finkel N, Deshpande A, Sharrow S, Rossi DJ, et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 2014; 514(7520):107-111
8. Toledo LI, Murga M and Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol. 2011; 5(4):368-373
9. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G and Denny CT. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A. 1993; 90(12):5752-5756
10. Spahn L, Petermann R, Siligan C, Schmid JA, Aryee DNT and Kovar H. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Research. 2002; 62(16):4583-4587
11. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570-575
12. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA and Chinnaiyan AM. PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma. Cancer Research. 2012; 72(7):1608-1613
13. Li H, Watford W, Li C, Parmelee A, Bryant MA, Deng C, O'Shea J and Lee SB. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. The Journal of clinical investigation. 2007; 117(5):1314-1323
14. Cho J, Shen H, Yu H, Li H, Cheng T, Lee SB and Lee BC. Ewing sarcoma gene Ews regulates hematopoietic stem cell senescence. Blood. 2011; 117(4):1156-1166
15. Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M, Lee Y, McKinnon PJ, Nussenzweig A and Fernandez-Capetillo O. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet. 2009; 41(8):891-898
16. Lecona E and Fernandez-Capetillo O. Replication stress and cancer: it takes two to tango. Exp Cell Res. 2014; 329(1):26-34
17. Zeman MK and Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014; 16(1):2-9
18. Dobbelstein M and Sorensen CS. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov. 2015; 14(6):405-423
19. Schulze J, Lopez-Contreras AJ, Uluckan O, Grana-Castro O, Fernandez-Capetillo O and Wagner EF. Fos-dependent induction of Chk1 protects osteoblasts from replication stress. Cell Cycle. 2014; 13(12):1980-1986
20. Lopez-Contreras AJ, Gutierrez-Martinez P, Specks J, Rodrigo-Perez S and Fernandez-Capetillo O. An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation. J Exp Med. 2012; 209(3):455-461
21. Krajewska M, Fehrmann RS, Schoonen PM, Labib S, de Vries EG, Franke L and van Vugt MA. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene. 2015; 34(26):3474-3481
22. Sarmento LM, Povoa V, Nascimento R, Real G, Antunes I, Martins LR, Moita C, Alves PM, Abecasis M, Moita LF, Parkhouse RM, Meijerink JP and Barata JT. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. Oncogene. 2014; 0
23. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-607
24. Kwok M, Davies N, Agathanggelou A, Smith E, Petermann E, Yates E, Brown J, Lau A and Stankovic T. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet. 2015; 385 Suppl 1:S58
25. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J and Bartek J. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 2005; 25(9):3553-3562
26. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR and Fernandez-Capetillo O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancerassociated mutations. Nat Struct Mol Biol. 2011; 18(6):721-727
27. Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM, Nissink JW, Odedra R, Page K, Perkins P, Suleman A, Tam K, et al. Discovery of 4-(4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l)-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013; 56(5):2125-2138
28. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suva ML, Benes CH, Haber DA, Boussin FD and Zou L. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015; 347(6219):273-277
29. Ruiz S, Mayor-Ruiz C, Lafarga V, Murga M, Vega-Sendino M, Ortega S and Fernandez-Capetillo O. A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. Mol Cell. 2016; 62(2):307-313
30. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM and Lozano G. EWS-FLI1 Induces Developmental Abnormalities and Accelerates Sarcoma Formation in a Transgenic Mouse Model. Cancer Research. 2008; 68(21):8968-8975
31. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA and Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72(7):1608-1613
32. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM and Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014; 14:813
33. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, Mosse YP, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011; 108(8):3336-3341
34. Altmeyer M, Neelsen KJ, Teloni F, Pozdnyakova I, Pellegrino S, Grofte M, Rask MB, Streicher W, Jungmichel S, Nielsen ML and Lukas J. Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). Nat Commun. 2015; 6:8088
35. Paronetto MP, Miñana B and Valcárcel J. The Ewing Sarcoma Protein Regulates DNA Damage-Induced Alternative Splicing. Molecular cell. 2011; 43(3):353-368
36. Jacome A, Gutierrez-Martinez P, Schiavoni F, Tenaglia E, Martinez P, Rodriguez-Acebes S, Lecona E, Murga M, Mendez J, Blasco MA and Fernandez-Capetillo O. NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity. EMBO J. 2015; 34(21):2604-2619
37. Jackson DA and Pombo A. Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J Cell Biol. 1998; 140(6):1285-1295
38. Sarmento LM, Povoa V, Nascimento R, Real G, Antunes I, Martins LR, Moita C, Alves PM, Abecasis M, Moita LF, Parkhouse RM, Meijerink JP and Barata JT. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. Oncogene. 2015; 34(23):2978-2990
39. Derenzini E, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B, Brighenti E, Righi S, Fuligni F, Ghelli Luserna Di Rora A, Ferrari A, Martinelli G, Pileri S and Zinzani PL. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget. 2015; 6(9):6553-6569. doi: 10.18632/oncotarget.2720
40. Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, Anderson KC and Tonon G. Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer Discov. 2015
41. Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, Zediak VP, Velez M, Bhandoola A and Brown EJ. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell. 2007; 1(1):113-126